Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MACH-1 Biodefense AO1
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Epidermal
01
Overview
MACH-1 Biodefense AO1 is a preclinical-stage nucleic acid vaccine program developed by Orlance. It utilizes the proprietary MACH-1 delivery platform, which employs a high-pressure "gene gun" to deliver microparticle-formulated DNA or RNA vaccines directly into the epidermis. This specific program targets a range of biodefense-relevant pathogens, including Ebola virus, Dengue virus, various encephalitis viruses, Hantavirus, and orthopoxviruses (xPox). The goal of the AO1 program is to generate robust immune responses against these high-priority threats using a needle-free, stable, and rapid-response delivery technology.
- Other names
- MACH-1 BiodefenseMACH1 BiodefenseMACH 1 BiodefenseAO1 - EbolaAO-1 - EbolaAO 1 - EbolaAO1 - DengueAO-1 - DengueAO 1 - DengueAO1 - EncephalitisAO-1 - EncephalitisAO 1 - EncephalitisAO1 - HantaAO-1 - HantaAO 1 - HantaAO1 - xPoxAO-1 - xPoxAO 1 - xPox
Beyond the preview
Go deeper on MACH-1 Biodefense AO1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MACH-1 Biodefense AO1.